NCT06232109

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Asceneuron S.A. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51

Conditions

• Drug Drug Interaction

Interventions

Type	Name	Description
DRUG	Fluvoxamine	Oral
DRUG	Itraconazole	Oral
DRUG	Paroxetine	Oral
DRUG	ASN51	Oral

Timeline

• Start date: 2024-02-22
• Primary completion: 2024-07-03
• Completion: 2024-07-03
• First posted: 2024-01-30
• Last updated: 2024-12-18

Locations

1 site across 1 country: Netherlands